Regencell Financial Statements From 2010 to 2026

RGC Stock  USD 31.90  0.33  1.05%   
Regencell Bioscience's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Regencell Bioscience's valuation are provided below:
Market Capitalization
15.6 B
Earnings Share
(0.01)
We have found one hundred twenty available trending fundamental ratios for Regencell Bioscience, which can be analyzed and compared to other ratios and to its competitors. Investors should ensure to check out all of Regencell Bioscience's recent performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road.

Regencell Bioscience Total Revenue

0.0

Check Regencell Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regencell Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 335.8 K, Interest Expense of 19.8 K or Selling General Administrative of 2.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.6 K. Regencell financial statements analysis is a perfect complement when working with Regencell Bioscience Valuation or Volatility modules.
  
Build AI portfolio with Regencell Stock
Check out the analysis of Regencell Bioscience Correlation against competitors.

Regencell Bioscience Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets4.9 M5.2 M1.2 B
Slightly volatile
Short and Long Term Debt Total465.5 K490 K928.2 M
Slightly volatile
Total Current Liabilities567.4 K597.3 K218.3 M
Slightly volatile
Property Plant And Equipment Net649.6 K683.8 K712.2 M
Slightly volatile
Current Deferred Revenue224.8 M214.1 M170 M
Slightly volatile
Accounts Payable200 M267 M210 M
Slightly volatile
Cash2.1 M2.2 M104.7 M
Slightly volatile
Cash And Short Term Investments4.2 M4.4 M107.2 M
Slightly volatile
Good Will266.7 M397.7 M317.7 M
Slightly volatile
Common Stock Shares Outstanding422.8 M445 M2.7 B
Slightly volatile
Liabilities And Stockholders Equity4.9 M5.2 M1.2 B
Slightly volatile
Non Current Liabilities Total198 K208.5 K1.2 B
Slightly volatile
Other Current AssetsK5.2 K27.4 M
Slightly volatile
Total Liabilities765.5 K805.8 K1.4 B
Slightly volatile
Total Current Assets4.2 M4.4 M191.5 M
Slightly volatile
Short Term Debt267.4 K281.5 K13.9 M
Slightly volatile
Intangible Assets38.4 M50.1 M41.7 M
Slightly volatile
Net Receivables130.6 K137.5 K61.7 M
Slightly volatile
Common Stock4.2 K4.5 K47.9 K
Slightly volatile
Common Stock Total Equity85.590.047.1 K
Slightly volatile
Property Plant And Equipment Gross864.1 K909.6 K661.8 M
Slightly volatile
Short and Long Term Debt3.2 M4.2 M2.8 M
Slightly volatile
Capital Stock126150112
Slightly volatile
Property Plant Equipment1.8 M1.7 M614.5 K
Slightly volatile
Deferred Long Term Liabilities137.9 K155.1 K169.3 K
Slightly volatile

Regencell Bioscience Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization335.8 K353.5 K96.7 M
Slightly volatile
Selling General Administrative2.8 M2.9 M86.5 M
Slightly volatile
Other Operating Expenses3.2 M3.4 M1.2 B
Slightly volatile
Cost Of Revenue335.8 K353.5 K180.2 M
Slightly volatile
Total Operating Expenses2.9 MM638.3 M
Slightly volatile
Selling And Marketing Expenses97.7 K144.2 K54.7 K
Slightly volatile
Research Development1.1 M1.1 M659 K
Slightly volatile

Regencell Bioscience Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.5 M2.7 M90.9 M
Slightly volatile
Depreciation335.8 K353.5 K96.7 M
Slightly volatile
Dividends Paid191.8 M125 M151.1 M
Very volatile
End Period Cash Flow2.1 M2.2 M104.7 M
Slightly volatile
Change To Netincome2.2 M2.3 M2.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.420.457.5127
Slightly volatile
Cash Per Share0.00960.00890.0063
Slightly volatile
Income Quality0.640.780.8395
Slightly volatile
Current Ratio11.16.656.8149
Slightly volatile
Capex Per Share5.0E-44.0E-44.0E-4
Pretty Stable
Interest Debt Per Share0.00120.00130.0035
Slightly volatile
Debt To Assets0.10.115.5411
Slightly volatile
Ebt Per Ebit1.061.090.9829
Slightly volatile
Effective Tax Rate8.0E-49.0E-40.001
Slightly volatile
Quick Ratio11.126.656.8244
Slightly volatile
Net Income Per E B T0.780.890.9611
Slightly volatile
Cash Ratio3.763.282.4032
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.181.211.1391
Slightly volatile
Debt Ratio0.10.115.5411
Slightly volatile

Regencell Bioscience Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap6.7 B7.6 B8.3 B
Slightly volatile
Enterprise Value6.7 B7.6 B8.3 B
Slightly volatile

Regencell Fundamental Market Drivers

Regencell Upcoming Events

26th of January 2024
Upcoming Quarterly Report
View
30th of September 2023
Next Fiscal Quarter End
View

About Regencell Bioscience Financial Statements

Regencell Bioscience stakeholders use historical fundamental indicators, such as Regencell Bioscience's revenue or net income, to determine how well the company is positioned to perform in the future. Although Regencell Bioscience investors may analyze each financial statement separately, they are all interrelated. For example, changes in Regencell Bioscience's assets and liabilities are reflected in the revenues and expenses on Regencell Bioscience's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Regencell Bioscience Holdings. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue214.1 M224.8 M
Cost Of Revenue353.5 K335.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:
Check out the analysis of Regencell Bioscience Correlation against competitors.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Will Biotechnology sector continue expanding? Could Regencell diversify its offerings? Factors like these will boost the valuation of Regencell Bioscience. Anticipated expansion of Regencell directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Regencell Bioscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.01)
Return On Assets
(0.33)
Return On Equity
(0.55)
Investors evaluate Regencell Bioscience using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Regencell Bioscience's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Regencell Bioscience's market price to deviate significantly from intrinsic value.
It's important to distinguish between Regencell Bioscience's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Regencell Bioscience should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Regencell Bioscience's market price signifies the transaction level at which participants voluntarily complete trades.